SCHEMBL15437751

SCHEMBL15437751

O=C(O)c1ccc(N2C(=O)C(c3ccccc3)=C(c3ccccc3)C2=O)cc1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM3 Q86V86 1/20 0.73
HIPK4 Q8NE63 1/20 0.73
SCN2A Q99250 1/20 0.73
TYMS P04818 1/20 0.56
HNF4A P41235 1/20 0.54
ACMSD Q8TDX5 1/20 0.54
ALDH1A1 P00352 4/20 0.54
KDM4E B2RXH2 3/20 0.54
POLB P06746 2/20 0.54
HPGD P15428 2/20 0.54
MAPK1 P28482 1/20 0.54
HSD17B10 Q99714 1/20 0.54
MEN1 O00255 1/20 0.52
PKM P14618 1/20 0.52
KMT2A Q03164 1/20 0.52
DUSP3 P51452 2/20 0.52
DUSP22 Q9NRW4 1/20 0.52
MYC P01106 2/20 0.49
KLKB1 P03952 1/20 0.49
CTSB P07858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15437835 0.88 PIM3 (0.56) PIM3HIPK4SCN2ATYMSHNF4A
SCHEMBL38651889 0.84 SCN2A (1.00) PIM3HIPK4SCN2ATYMSALDH1A1
SCHEMBL24939840 0.80 PIM3 (0.69) PIM3HIPK4SCN2ATYMSALDH1A1
SCHEMBL21889940 0.78 PIM3 (0.77) PIM3HIPK4SCN2ATYMSALDH1A1
SCHEMBL24939830 0.76 PIM3 (0.64) PIM3HIPK4SCN2ATYMSALDH1A1
SCHEMBL29567433 0.76 PIM3 (0.64) PIM3HIPK4SCN2ATYMSALDH1A1
SCHEMBL3050771 0.76 PIM3 (0.64) PIM3HIPK4SCN2ATYMSALDH1A1
SCHEMBL16583897 0.75 PIM3 (0.76) PIM3HIPK4SCN2ATYMSALDH1A1
SCHEMBL14777408 0.72 NR1H2 (0.53) SCN2AALDH1A1MEN1PKMKMT2A
SCHEMBL29810721 0.71 ACMSD (1.00) HNF4AACMSDALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 US claimed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 US claimed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 US claimed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 US disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 US disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof SOST, MYD88, MSR1 PIM3 1474/4885HIPK4 412/4885SCN2A 4856/4885
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof SOST, MYD88, MSR1 PIM3 921/4885HIPK4 553/4885SCN2A 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.